Professor Jennifer Martin is a dual trained clinical pharmacologist and practising general physician. She has studied politics and health economics at Oxford University as a Rhodes Scholar and has used this experience to serve on the Pharmaceutical Benefits Advisory Committee, the Economic Subcommittee of the PBAC and other Government and Statewide committees examining appropriate allocation, regulation, safety and efficacy in pharmaceuticals.
Her PhD (Monash) examined innate immunity in Type 2 diabetes and subsequent postdoctoral work at the Walter and Eliza Hall focussed on the function of macrophages with high fat diet. Her recent research is in the area of clinical development of both novel and old drugs for a variety of diseases and has developed a collaboration with Leiden University using clinical pharmacological methods generally to improve dosing, with EKUT (Germany) in the combined role of therapeutic drug monitoring (TDM) and pharmacogenetics to individualise choice and dose of chemotherapy, and with the National Institutes of Health in identifying and managing synthetic drugs of abuse.
Professor Martin’s current PhD students are researching cannabinoid therapies, targeted cancer therapies, dosing in neonates and therapeutic drug monitoring in clinical care including with antimicrobial therapies.
Professor Martin is currently a member of the RACP Policy and Advocacy Committee, the Council of the Australasian Society for Clinical and Experimental Pharmacology and Therapeutics, and a member of the Pharmacology and Therapeutics Advisory Committee of PHARMAC, the sole purchaser for pharmaceuticals in New Zealand.
